Myelofibrosis Clinical Trial Update: The Science Behind JAK Inhibitors

Myelofibrosis Clinical Trial Update: The Science Behind JAK Inhibitors

P2Professional

2 years
2,760 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
With the knowledge clinicians are gaining about the driver mutations of myeloproliferative neoplasms (MPNs), JAK inhibitors have become more recognized as a personalized, targeted therapy. But how do JAK inhibitors actually work? Dr. David Snyder from City of Hope explains what these medicines actual inhibit and goes on to discuss different variations of JAK inhibitors. Dr. Snyder shares information about approved JAK inhibitors and others in clinical trials, such as the PAC203 trial for pacritinib. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Up Next Autoplay
ASH 2017: New Drugs and Numerous Drug Combinations in Myeloma
ASH 2017: New Drugs and Numerous Drug Combinations in Myeloma
Category: Acute Lymphoblastic Leukemia
1,300 Views
P2Professional 1 year
Treatment News in Lymphoma From ASH 2017
Treatment News in Lymphoma From ASH 2017
Category: Acute Lymphoblastic Leukemia
1,141 Views
P2Professional 1 year
Making Treatment Decisions in Myeloma: How Do I Know What’s Right for Me?
Making Treatment Decisions in Myeloma: How Do I Know What’s Right for Me?
Category: Acute Lymphoblastic Leukemia
974 Views
P2Professional 1 year
ROR1: An Update From ASH 2017
ROR1: An Update From ASH 2017
Category: Acute Lymphoblastic Leukemia
1,263 Views
P2Professional 1 year
ASH 2017: CLL Combination Therapy News
ASH 2017: CLL Combination Therapy News
Category: Acute Lymphoblastic Leukemia
1,057 Views
P2Professional 1 year
ASH 2017: Are Experts Personalizing Therapy to the Genetics of a Patient’s Myeloma?
ASH 2017: Are Experts Personalizing Therapy to the Genetics of a Patient’s Myeloma?
Category: Acute Lymphoblastic Leukemia
554 Views
P2Professional 1 year
CAR T-Cell Therapy Update From ASH 2017
CAR T-Cell Therapy Update From ASH 2017
Category: Acute Lymphoblastic Leukemia
175 Views
P2Professional 1 year
What the MPN Experts Learned at ASH 2017
What the MPN Experts Learned at ASH 2017
Category: Acute Lymphoblastic Leukemia
146 Views
P2Professional 1 year
ASH 2017: Promising Mantle Cell Lymphoma Treatment News
ASH 2017: Promising Mantle Cell Lymphoma Treatment News
Category: Acute Lymphoblastic Leukemia
404 Views
P2Professional 1 year
CAR T-Cell Therapy News From ASH 2017
CAR T-Cell Therapy News From ASH 2017
Category: Acute Lymphoblastic Leukemia
324 Views
P2Professional 1 year